BNP Paribas Financial Markets’s Fulgent Genetics FLGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.27M | Buy |
62,089
+32,665
| +111% | +$554K | ﹤0.01% | 3146 |
|
|
2026
Q1 | $468K | Sell |
29,424
-835
| -3% | -$18.1K | ﹤0.01% | 3632 |
|
|
2025
Q4 | $795K | Sell |
30,259
-110,468
| -78% | -$2.87M | ﹤0.01% | 3270 |
|
|
2025
Q3 | $3.18M | Buy |
140,727
+53,409
| +61% | +$1.1M | ﹤0.01% | 2286 |
|
|
2025
Q2 | $1.74M | Buy |
87,318
+2,128
| +2% | +$41.5K | ﹤0.01% | 2573 |
|
|
2025
Q1 | $1.44M | Buy |
85,190
+36,663
| +76% | +$624K | ﹤0.01% | 2544 |
|
|
2024
Q4 | $896K | Buy |
48,527
+4,714
| +11% | +$92K | ﹤0.01% | 2902 |
|
|
2024
Q3 | $952K | Buy |
43,813
+30,160
| +221% | +$674K | ﹤0.01% | 2526 |
|
|
2024
Q2 | $268K | Sell |
13,653
-3,126
| -19% | -$65.3K | ﹤0.01% | 2982 |
|
|
2024
Q1 | $364K | Buy |
16,779
+5,043
| +43% | +$125K | ﹤0.01% | 3012 |
|
|
2023
Q4 | $339K | Sell |
11,736
-8,060
| -41% | -$216K | ﹤0.01% | 3009 |
|
|
2023
Q3 | $529K | Buy |
19,796
+14,064
| +245% | +$480K | ﹤0.01% | 2696 |
|
|
2023
Q2 | $212K | Sell |
5,732
-11,496
| -67% | -$401K | ﹤0.01% | 2990 |
|
|
2023
Q1 | $538K | Buy |
17,228
+8,319
| +93% | +$268K | ﹤0.01% | 2692 |
|
|
2022
Q4 | $265K | Sell |
8,909
-4,518
| -34% | -$162K | ﹤0.01% | 2887 |
|
|
2022
Q3 | $512K | Buy |
13,427
+1,498
| +13% | +$75.1K | ﹤0.01% | 2967 |
|
|
2022
Q2 | $650K | Sell |
11,929
-894
| -7% | -$49.1K | ﹤0.01% | 2510 |
|
|
2022
Q1 | $800K | Sell |
12,823
-11,012
| -46% | -$725K | ﹤0.01% | 2465 |
|
|
2021
Q4 | $2.4M | Sell |
23,835
-2,107
| -8% | -$185K | ﹤0.01% | 1871 |
|
|
2021
Q3 | $2.33M | Buy |
25,942
+13,525
| +109% | +$1.23M | ﹤0.01% | 1785 |
|
|
2021
Q2 | $1.15M | Buy |
12,417
+4,945
| +66% | +$395K | ﹤0.01% | 2099 |
|
|
2021
Q1 | $722K | Buy |
7,472
+4,502
| +152% | +$465K | ﹤0.01% | 2343 |
|
|
2020
Q4 | $155K | Buy |
2,970
+632
| +27% | +$26.4K | ﹤0.01% | 3002 |
|
|
2020
Q3 | $93.6K | Buy |
2,338
+1,976
| +546% | +$61.9K | ﹤0.01% | 3151 |
|
|
2020
Q2 | $5.79K | Buy |
+362
| New | +$5.54K | ﹤0.01% | 3945 |
|
|
2019
Q4 | – | Sell |
-1
| Closed | -$10 | – | 4445 |
|
|
2019
Q3 | $10 | Hold |
1
| – | – | ﹤0.01% | 4486 |
|
|
2019
Q2 | $7 | Hold |
1
| – | – | ﹤0.01% | 4515 |
|
|
2019
Q1 | $6 | Hold |
1
| – | – | ﹤0.01% | 4262 |
|
|
2018
Q4 | $3 | Hold |
1
| – | – | ﹤0.01% | 4309 |
|
|
2018
Q3 | $4 | Hold |
1
| – | – | ﹤0.01% | 4427 |
|
|
2018
Q2 | $4 | Hold |
1
| – | – | ﹤0.01% | 4405 |
|
|
2018
Q1 | $4 | Hold |
1
| – | – | ﹤0.01% | 4209 |
|
|
2017
Q4 | $4 | Hold |
1
| – | – | ﹤0.01% | 4214 |
|
|
2017
Q3 | $5 | Hold |
1
| – | – | ﹤0.01% | 4230 |
|
|
2017
Q2 | $6 | Sell |
1
-13
| -93% | -$105 | ﹤0.01% | 4245 |
|
|
2017
Q1 | $153 | Sell |
14
-1,152
| -99% | -$13.6K | ﹤0.01% | 3969 |
|
|
2016
Q4 | $13.5K | Buy |
+1,166
| New | +$11K | ﹤0.01% | 3330 |
|
Other funds holding FLGT
DC
BNP Paribas Financial Markets's FLGT Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Fulgent Genetics (FLGT) stake by 111% in Q2 2026, buying an estimated $554K and bringing the position to 62,089 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3146.
BNP Paribas Financial Markets first reported a position in FLGT in Q4 2016 and has held it in 37 quarters since. The position peaked at $3.18M in Q3 2025. 138 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.
- BNP Paribas Financial Markets held 62,089 shares of Fulgent Genetics worth $1.27M as of Q2 2026.
- BNP Paribas Financial Markets bought 32,665 Fulgent Genetics shares in Q2 2026, an estimated $554K.
- Fulgent Genetics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3146 holding.
- BNP Paribas Financial Markets first reported a position in Fulgent Genetics in Q4 2016 and has held it in 37 quarters since.
- BNP Paribas Financial Markets's Fulgent Genetics position peaked at $3.18M in Q3 2025.
- 138 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.